J&J COVID-19 vaccine should be used but carry blood clot warning

Subjects ” General neurology

HealthDay News – A warning of a possible association with rare blood clots should be added to Johnson & Johnson / Janssen’s COVID-19 single-dose vaccine, the European Union (EU) Medicines Agency said Tuesday.

However, the European Medicines Agency (EMA) also said the vaccine’s benefits far outweigh the risks and did not recommend member states avoid using the vaccine, the New York Times reported. “The reported combination of blood clots and low platelets is very rare, and the general benefits of the COVID-19 vaccine Janssen in preventing COVID-19 outweigh the risk of side effects,” the agency said in a statement accompanying its non-binding recommendation.

The rare clots associated with the Johnson & Johnson vaccine are very similar to those associated with the AstraZeneca vaccine, which the EMA has made a similar recommendation for, The Times reported.

Continue reading

“Health professionals and people receiving the vaccine should be aware of the possibility of very rare cases of blood clots combined with low platelet levels within three weeks of vaccination,” the agency advised. An immune response could be a possible explanation for the rare blood clots.

The Johnson & Johnson vaccine has been given to nearly 8 million people in the United States. However, US regulators stopped using the vaccine last week over concerns about six cases of the rare blood clots. This resulted in Johnson & Johnson delaying the launch of the vaccine in the 27 EU member states, The Times reported. US health officials said Monday they are investigating “a handful” of new, unconfirmed cases that have occurred since the vaccine was discontinued.

The New York Times article


COVID19 General Infectious Disease General Neurology

Would you like to read more?

Please log in or register first to view this content.

Login Register

to open

Next post in General Neurology

Shut down

Related Articles